As already demonstrated in CML, BMI1 is responsible for the resistance to the tyrosine kinase inhibitors (TKIs) in a BCR-ABL1-independent way. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.